Journal of the American Society of Hypertension
Volume 1, Issue 3 , Pages 178-184 , May 2007

Chronic kidney disease and cardiovascular risk

  • Preethi Yerram, MD, MSG

      Affiliations

    • Department of Internal Medicine, University of Missouri School of Medicine, Columbia, Missouri, USA
    • Corresponding Author InformationCorresponding author: Preethi Yerram, MD, MSG, Department of Internal Medicine, University of Missouri School of Medicine, Health Sciences Center, MA406, Columbia, Missouri 65212. Tel: 573-234-4137; fax: 573-884-4820.
    • ,
  • Poorna R. Karuparthi, MD

      Affiliations

    • Department of Internal Medicine, University of Missouri School of Medicine, Columbia, Missouri, USA
    • ,
  • Laura Hesemann, MD

      Affiliations

    • Department of Internal Medicine, University of Missouri School of Medicine, Columbia, Missouri, USA
    • ,
  • Jennifer Horst, MD

      Affiliations

    • Department of Internal Medicine, University of Missouri School of Medicine, Columbia, Missouri, USA
    • ,
  • Adam Whaley-Connell, DO, MSPH

      Affiliations

    • Department of Internal Medicine, University of Missouri School of Medicine, Columbia, Missouri, USA
    • Division of Nephrology, University of Missouri School of Medicine, Columbia, Missouri, USA

Received 9 December 2006 ,Accepted 30 January 2007.

References 

  1. Fried L, Kronmal R, Newman A, et al. Cardiovascular Health Study Collaborative Research Group Risk Factors for 5-Year Mortality in Older Adults: the Cardiovascular Health Study JAMA. 1998;279:585–592
  2. Mann J, Gerstein H, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629–636
  3. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med. 2001;161:886–891
  4. Shulman N, Ford C, Hall W, et al. The Hypertension Detection and Follow-up Program Cooperative Group Hypertension Prognostic value of serum creatinine and effect of treatment of hypertension on renal function (Results from the hypertension detection and follow-up program). Hypertension. 1989;13:I80–I93
  5. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int. 2003;64(Suppl 87):S24–S31
  6. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis. 2003;42:677–684
  7. Levey AS, Beto JA, Coronado BE, et al. National Kidney Foundation Task Force on Cardiovascular Disease Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here?. Am J Kidney Dis. 1998;32:853–906
  8. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112–S119
  9. Kasper D, Braunwald E, Fauci A, Hauser S, Longo D, Jameson J. In: Harrison’s Principles of Internal Medicine. 16th ed.. New York, New York: McGraw-Hill; 2005;p. 1653–1663
  10. Sarnak M, Levey A, Schoolwerth A, Coresh J. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–2159
  11. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol. 2006;1:8–18
  12. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. [see comment] N Engl J Med. 2004;351:1296–1305
  13. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000;35(4 Suppl 1):S117–S131
  14. Block G, Port FK. Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease. Semin Dial. 2003;16:140–147
  15. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults findings from The Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359
  16. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–174[see comment]
  17. Muntner P, He J, Chen J, Fonseca V, Whelton P. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol. 2004;14:6686–6695
  18. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. [see comment] J Am Soc Nephrol. 2005;16:2134–2140
  19. Kahn R, Buse J, Ferrannini E, Stern M Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal. Diabetologia. 2005;48:1684–1699
  20. Shlipak M, Fried L, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87–92
  21. Foley R, Parfrey P, Harnett J, Kent G, Murray D, Barre P. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61
  22. Blacher J, Safar M, Guerin A, Pannier B, Marchais S, London G. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int. 2003;63:1852–1860
  23. Rostand S, Dreke T. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 1999;56:383–392
  24. Jono S, McKee MD, Murry C, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:e10–e17.
  25. Guerin A, London G, Marchais S, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014–1021
  26. Stevens LA, Levin A. Anaemia, cardiovascular disease and kidney disease: integrating new knowledge in 2002. Curr Opin Nephrol Hypertens. 2003;12:133–138
  27. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero J. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis. 1997;29:541–548
  28. Besarab A, Bolton W, Browne J, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  29. Foley R, Parfrey P, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325–1335
  30. Malinow M, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)inemia in daily practice: levels in coronary heart disease. Coron Artery Dis. 1990;1:215–220
  31. Boston A, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcome. Kidney Int. 1997;52:10–20
  32. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?. Kidney Int. 2001;59:407–414
  33. Ridker P, Cushman M, Stampher M, Tracy RP, Hennekens C. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:976–979
  34. Varagunam M, Finney H, Trevitt R, et al. Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis. 2004;43:502–507
  35. Noh H, Lee S, Kang S, et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1998;18:387–394
  36. Defilipp C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. 2003;290:353–359
  37. Knight E, Rimm E, Pai J, et al. Kidney dysfunction, inflammation, and coronary events: a Prospective Study. J Am Soc Nephrol. 2004;15:1897–1903
  38. Galli F, Canestrari F, Buoncristani U. Biological effects of oxidant stress in haemodialysis: the possible roles of vitamin E. Blood Purif. 1999;17:79–94
  39. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  40. Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461–470
  41. Levey A, Greene T, Kusek J, Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine. [abstract] J Am Soc Nephrol. 2000;11:155A
  42. Keane W, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis. 1999;33:1004–1010
  43. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448–1456
  44. Cohn J, Quyyumi A, Hollenberg N, Jamerson K. Surrogate markers for cardiovascular disease: functional markers. Circulation. 2004;109(25 Suppl 1):31–46
  45. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1–S266
  46. American Diabetes Association. Clinical practice recommendations. Diabetes Care. 2001;24:S1–S133
  47. Warram J, Gearin G, Laffel L, Krolewski A. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol. 1996;7:930–937
  48. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen J. Urinary albumin excretion (An independent predictor of ischemic heart disease). Arterioscler Thromb Vasc Biol. 1999;19:1992–1997
  49. ADA. ADA position statement: nephropathy in diabetes. Diabetes Care. 2004;27(Suppl 1):S79–S83
  50. Agodoa LY, Appel L, Bakris GL African-American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719–2728
  51. Brenner BM, Cooper ME, de Zeeuw D, et al. for the RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  52. Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  53. Weir MR. The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. Am J Hypertens. 2005;18:S100–S105
  54. Jamerson KA. Preventing chronic kidney disease in special populations. Am J Hypertens. 2005;18:S106–S111
  55. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 Report. JAMA. 2003;289:2560–2572

 Conflict of interest: none.

PII: S1933-1711(07)00040-X

doi: 10.1016/j.jash.2007.01.010

Journal of the American Society of Hypertension
Volume 1, Issue 3 , Pages 178-184 , May 2007

Article Tools

* Image Usage & Resolution